Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-group, controlled trial
DiscussionThe present study will be the first trial to evaluate the efficacy and safety of early treatment with the combination of standard-dose empagliflozin and colchicine as well as high-dose empagliflozin in non-diabetic patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction. The results of this research will represent a significant step forward in the treatment of patients with acute myocardial infarction.Trial registrationClinical trial ID: IRCT20111206008307N39. Registration date: 27 October 2022.Graphical Abstract
Source: Trials - Category: Research Source Type: clinical trials
More News: Angioplasty | Cardiology | Cardiovascular | Colchicine | Colcrys | Coronary Angioplasty | Diabetes | Empagliflozin | Endocrinology | Heart | Heart Attack | Heart Failure | Hospitals | Jardiance | Percutaneous Coronary Intervention | Research | Sodium | Study | Teaching | Universities & Medical Training